Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: December 20, 2024
Subject: Update on Share Repurchase Programme
Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 72,000 people across 80 countries. The filing reports on the execution of a share repurchase programme initiated on November 11, 2024, which is part of a broader DKK 20 billion programme authorized for a 12-month period beginning February 6, 2024.
Key Financial Metrics and Transaction Details
This filing focuses on capital allocation via share buybacks rather than operational financial performance (revenue, profit, or cash flow). Key metrics provided include:
- Total Repurchase Programme Cap: Up to DKK 20 billion.
- Current Sub-Programme Cap (Nov 11, 2024 - Feb 3, 2025): Up to DKK 3,136,206,122.30.
- Accumulated Repurchases (as of Dec 19, 2024): 22,514,974 B shares.
- Total Transaction Value (since Feb 6, 2024): DKK 18,612,125,800.
- Average Share Price (since Feb 6, 2024): DKK 826.66 per B share.
- Treasury Shares Held: 23,659,532 B shares (0.5% of share capital).
- Total Share Capital: 4,465,000,000 A and B shares (including treasury shares).
Note: The filing text does not provide clear values for revenue, profit, operating margins, debt levels, or liquidity ratios.
Material Changes and Recent Activity
The filing details specific transactions executed between December 16 and December 19, 2024, under the current sub-programme:
| Date | Number of B Shares | Average Purchase Price (DKK) | Transaction Value (DKK) |
|---|---|---|---|
| Dec 16, 2024 | 77,000 | 771.65 | 59,416,851 |
| Dec 17, 2024 | 79,896 | 766.17 | 61,214,109 |
| Dec 18, 2024 | 80,000 | 769.67 | 61,573,786 |
| Dec 19, 2024 | 79,000 | 756.23 | 59,742,420 |
| Accumulated (Current Programme) | 2,311,875 | - | 1,748,331,923 |
Recent transaction prices (approx. DKK 756–772) are lower than the overall average price of DKK 826.66 since the programme's inception in February 2024.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to continue repurchasing B shares up to the total limit of DKK 20 billion during the 12-month period starting February 6, 2024. As of December 19, 2024, approximately DKK 1.39 billion remains available under the total programme cap.
Regulatory Context: The programme is executed in accordance with Article 5 of Regulation No 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 (Safe Harbour Rules).
Risks/Contingencies: The filing does not explicitly list new risks or contingencies beyond the standard execution of the buyback programme.
Key Facts for Investor Verification
- Verify the remaining capacity of the DKK 20 billion share repurchase programme (approx. DKK 1.39 billion remaining as of Dec 19, 2024).
- Confirm the current market price of Novo Nordisk B shares relative to the recent average purchase price of DKK 756–772.
- Review the company's latest Form 20-F or quarterly reports for operational financial metrics (revenue, profit, cash flow) which are not included in this 6-K filing.
- Monitor the timeline for the conclusion of the 12-month repurchase period (February 2025).